Merl Man Yee, Li Jia, Saif Muhammad Wasif
Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA.
JOP. 2010 Mar 5;11(2):148-50.
Pancreatic cancer is sometimes called a "silent killer" because it is often not diagnosed until it is advanced. It remains the fourth leading cause of cancer-related death in the United States. Gemcitabine has been the front line therapy for advanced pancreatic cancer over the past 10 years. Over this time period, survival benefit has not been able to improve substantially from studies of gemcitabine-based combination therapy. A breakthrough to improve treatment options in this setting is needed. In the 2010 ASCO Gastrointestinal Cancers Symposium in Orlando, Florida, USA, several abstracts were presented to explore new agents or combinations as first-line therapy in locally advanced or metastatic settings. In this article, we review and summarize the findings from these studies.
胰腺癌有时被称为“沉默的杀手”，因为它往往在病情进展到晚期时才被诊断出来。在美国，它仍然是癌症相关死亡的第四大主要原因。在过去10年里，吉西他滨一直是晚期胰腺癌的一线治疗药物。在此期间，基于吉西他滨的联合治疗研究未能显著提高生存率。在这种情况下，需要取得突破以改善治疗选择。在美国佛罗里达州奥兰多市举行的2010年美国临床肿瘤学会胃肠道癌症研讨会上，有几篇摘要探讨了在局部晚期或转移性情况下作为一线治疗的新药物或联合疗法。在本文中，我们回顾并总结了这些研究的结果。
